Alnylam Pharmaceuticals, Inc. (ALNY)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS02043Q1076
165.12 USD
+5.40% today Updated 13 Nov 2026 16:31
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Alnylam Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:31. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
11 Feb 2027
in 90 days · 08:00 · estimate 2.42
Last results
16.26 vs 2.25 estimated
29 Oct 2026 · Beat +623.0%
Beat the estimate
8 of 12
3 missed · 1 in line
Average surprise
+106.8%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 11 Feb 2027 08:00 | 2.42 | — | — | Upcoming |
| 29 Oct 2026 08:00 | 2.25 | 16.26 | +623.0% | Beat |
| 30 Jul 2026 08:00 | 2.14 | 1.84 | -14.2% | Miss |
| 30 Apr 2026 08:00 | 1.47 | 1.99 | +35.3% | Beat |
| 12 Feb 2026 08:00 | 1.50 | 1.25 | -16.5% | Miss |
| 30 Oct 2025 08:00 | 1.75 | 2.90 | +66.1% | Beat |
| 31 Jul 2025 08:00 | 0.15 | 0.32 | +119.6% | Beat |
| 01 May 2025 08:00 | -0.37 | -0.01 | +97.3% | Beat |
| 13 Feb 2025 08:00 | -0.14 | 0.06 | +142.5% | Beat |
| 31 Oct 2024 08:00 | -0.39 | -0.50 | -26.7% | Miss |
| 01 Aug 2024 08:00 | -0.69 | 0.56 | +181.1% | Beat |
| 02 May 2024 08:00 | -0.63 | -0.16 | +74.5% | Beat |
| 15 Feb 2024 08:00 | -0.77 | -0.77 | -0.2% | In line |
| 02 Nov 2023 08:00 | -0.96 | 1.74 | +281.9% | Beat |
| 03 Aug 2023 08:00 | -1.34 | -1.62 | -21.2% | Miss |
| 04 May 2023 08:00 | -1.43 | -1.06 | +25.7% | Beat |
| 23 Feb 2023 08:00 | -1.48 | -1.39 | +6.3% | Beat |
| 27 Oct 2022 08:00 | -1.38 | -1.58 | -14.6% | Miss |
| 28 Jul 2022 08:00 | -1.36 | -2.03 | -49.4% | Miss |
| 28 Apr 2022 08:00 | -1.46 | -1.49 | -2.1% | Miss |
| 10 Feb 2022 08:00 | -1.26 | -1.69 | -34.4% | Miss |
| 28 Oct 2021 08:00 | -1.24 | -1.51 | -21.4% | Miss |
| 03 Aug 2021 08:00 | -1.28 | -1.30 | -1.2% | Miss |
| 29 Apr 2021 08:00 | -1.40 | -1.64 | -17.1% | Miss |
| 11 Feb 2021 08:00 | -1.38 | -1.60 | -15.9% | Miss |
| 05 Nov 2020 08:00 | -1.34 | -1.58 | -18.0% | Miss |
| 06 Aug 2020 08:00 | -1.40 | -1.67 | -19.4% | Miss |
| 06 May 2020 09:00 | -1.51 | -1.52 | -0.9% | In line |
| 06 Feb 2020 08:00 | -1.92 | -1.98 | -3.1% | Miss |
| 31 Oct 2019 08:00 | -1.83 | -1.50 | +18.1% | Beat |
| 06 Aug 2019 07:00 | -1.85 | -1.83 | +1.2% | Beat |
| 01 May 2019 08:00 | -1.80 | -1.42 | +21.1% | Beat |
| 07 Feb 2019 16:00 | -1.93 | -1.82 | +5.7% | Beat |
| 07 Nov 2018 08:00 | -1.79 | -1.56 | +12.9% | Beat |
| 02 Aug 2018 08:00 | -1.71 | -1.83 | -6.9% | Miss |
| 03 May 2018 16:00 | -1.51 | -1.41 | +6.4% | Beat |
| 08 Feb 2018 08:00 | -1.36 | -1.48 | -8.7% | Miss |
| 07 Nov 2017 16:00 | -1.23 | -1.34 | -9.3% | Miss |
| 09 Aug 2017 16:00 | -1.17 | -1.34 | -14.7% | Miss |
| 05 May 2017 08:00 | -1.24 | -1.25 | -0.5% | In line |
| 08 Feb 2017 16:00 | -1.31 | -1.32 | -0.9% | In line |
| 02 Nov 2016 16:00 | -1.16 | -1.21 | -4.0% | Miss |
| 04 Aug 2016 16:00 | -1.27 | -1.05 | +17.4% | Beat |
| 02 May 2016 16:00 | -1.08 | -1.21 | -11.9% | Miss |
| 11 Feb 2016 16:00 | -0.92 | -1.07 | -16.0% | Miss |
| 09 Nov 2015 07:00 | -0.90 | -0.91 | -1.5% | Miss |
| 06 Aug 2015 16:00 | -0.73 | -0.85 | -16.8% | Miss |
| 07 May 2015 16:00 | -0.60 | -0.62 | -2.7% | Miss |
| 12 Feb 2015 16:00 | -0.57 | -0.28 | +50.9% | Beat |
| 05 Nov 2014 16:00 | -0.64 | -0.58 | +9.0% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 3.7B | +65.2% | 313.7M | 8.4% | 2.33 | +206.9% | 465.4M |
| 2024 | 2.2B | +23.0% | -278.2M | -12.4% | -2.18 | +38.1% | -42.6M |
| 2023 | 1.8B | +76.2% | -440.2M | -24.1% | -3.52 | +62.2% | 41.9M |
| 2022 | 1B | — | -1.1B | -109.0% | -9.30 | — | -613.3M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 163.10 | 170.49 | 149.18 | 165.12 | +0.07% | 32,290,039 | |
| Oct 2026 | 248.21 | 251.71 | 163.30 | 165.00 | -33.13% | 47,052,600 | |
| Sep 2026 | 242.40 | 272.08 | 236.00 | 246.74 | +2.51% | 31,156,500 | |
| Aug 2026 | 208.04 | 244.03 | 208.04 | 240.69 | +17.11% | 38,918,000 | |
| Jul 2026 | 304.54 | 380.00 | 197.81 | 205.52 | -31.73% | 45,402,900 | |
| Jun 2026 | 299.51 | 310.53 | 273.11 | 301.03 | -0.31% | 26,686,500 | |
| May 2026 | 308.76 | 311.88 | 284.28 | 301.98 | -2.43% | 20,110,900 | |
| Apr 2026 | 332.69 | 343.36 | 287.00 | 309.49 | -6.46% | 23,229,100 | |
| Mar 2026 | 329.41 | 334.42 | 299.62 | 330.87 | -0.62% | 25,990,000 | |
| Feb 2026 | 337.42 | 355.49 | 298.00 | 332.92 | -1.52% | 29,135,200 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- What Moved Alnylam Stock? (opens in a new tab) Trefis · 12 Nov 2026 15:13
- RNA Interference (RNAi) - Global Strategic Business Report: Capture the US$8 Billion 2032 Market as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Qiagen, Benitec BioPharma, and Silence Therapeutics (opens in a new tab) 12 Nov 2026 14:06
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Emerges as a Decent Value Stock (opens in a new tab) ChartMill · 12 Nov 2026 12:01
- Gene Therapy - Global Strategic Business Report: Capitalize on 23% CAGR as the Market Hits US$6 Billion by 2030; Benchmark Amgen, Alnylam, BioMarin, Biogen and bluebird bio (opens in a new tab) 11 Nov 2026 14:10
- Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD (opens in a new tab) 10 Nov 2026 15:00
- Alnylam And Regeneron Says Data Published In The The New England Journal Of Medicine, Reports Up To 80% Reduction In Liver Fat Sustained For 36 Weeks After Single CIDEBsiRNA Dose In MASLD Patients (opens in a new tab) Benzinga · 10 Nov 2026 11:02
- Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM (opens in a new tab) 09 Nov 2026 15:50
- Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down (opens in a new tab) BioPharma Dive · 06 Nov 2026 13:13
- Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership (opens in a new tab) 04 Nov 2026 22:15
- Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference (opens in a new tab) 04 Nov 2026 13:00
- What Could Alnylam Pharmaceuticals (ALNY) Five Year HELIOS B Data Change? (opens in a new tab) Simply Wall St. · 04 Nov 2026 01:08
- Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026 (opens in a new tab) 03 Nov 2026 13:30
- Alnylam Pharmaceuticals To Present New Helios-B Clinical Data At American Heart Association Scientific Sessions 2026 (opens in a new tab) Benzinga · 03 Nov 2026 09:33
- Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380 (opens in a new tab) Benzinga · 02 Nov 2026 16:06
- Should You Buy The Dip In Alnylam Stock? (opens in a new tab) Trefis · 02 Nov 2026 14:39
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 156.65 USD
- Market cap
- 21.0B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow ALNY and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.